Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Download: introducing the 10 Things That Matter in AI Right Now

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: introducing the 10 Things That Matter in AI Right Now Date: 2026-04-22 12:10 Source: https://www.technologyreview.com/2026/04/22/1136310/the-download-10-things-that-matter-in-ai-right-now/ <p><em>This is today’s edition of </em><a href="https://forms.technologyre…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Mythos model was too dangerous for a full release

    60% confidence

  • Trump threatened to destroy possibly all desalinization plants in Iran if the Strait of Hormuz is not reopened

    60% confidence

  • ChatGPT bot is not responsible for the Florida State shooting

    60% confidence

  • We can beat aging by adding youthful tissue to people's brains and eventually replace body parts including the brain

    60% confidence

  • I was very impressed with myself to have the head of Apple calling to 'kiss my ass'

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
The Download: introducing the 10 Things That Matter in AI Right Now — Source | Via News | ViaNews EU